Quantitative-imaging in Cardiac Transthyretin Amyloidosis

Abroad (travel likely)Recruiting

Conditions

ATTR-CM

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Medical Centre Groningen, Groningen, Netherlands
Contact: Study coordinator (Riemer HJ Slart, MD PhD) · r.h.j.a.slart@umcg.nl · +31 50 361 1835

Study leads

Marc Dweck, MD PhD
Principal Investigator
Centre of Cardiovascular Science
Fabien Siepen, MD PhD
Principal Investigator
Heidelberg University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Abroad (travel likely)Recruiting

Heidelberg, Germany

Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

ATTR-CM

Abroad (travel likely)Recruiting

Beijing, China · Beijing, China

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Transthyretin Amyloidosis · ATTR-CM · ATTRv-PN

Abroad (travel likely)Recruiting

La Jolla, United States · Los Angeles, United States

US Benchmarking Clinical Study

HFpEF - Heart Failure With Preserved Ejection Fraction · HFmrEF · ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Abroad (travel likely)Recruiting

Boston, United States · Boston, United States